Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.

Published on Sep 1, 2021in Endocrine Pathology3.168
· DOI :10.1007/S12022-020-09647-W
Tae Nakano-Tateno3
Estimated H-index: 3
(U of A: University of Alberta),
Motoyasu Satou2
Estimated H-index: 2
(U of A: University of Alberta)
+ 5 AuthorsConstance L. Chik29
Estimated H-index: 29
(U of A: University of Alberta)
Sources
Abstract
Corticotroph carcinomas and aggressive corticotroph tumors can be resistant to conventional therapy, including surgery, radiotherapy, and medical treatment. Recent evidence suggests that temozolomide (an oral alkylating agent) administered with capecitabine (pro-drug of 5-fluorouracil) may improve progression-free survival in patients with high-risk corticotroph tumors and carcinomas. This led to the use of capecitabine and temozolomide (CAPTEM) in two patients, one with a corticotroph carcinoma and the other with an aggressive corticotroph tumor, as well the in vitro analysis of capecitabine and 5-fluorouracil on cell growth and hormone production. Both patients had previous surgical and radiation therapy. The first patient developed leptomeningeal spread 2 years after his radiation treatment. He had 12 cycles of CAPTEM, which resulted in tumor control associated with clinical and radiological improvement. Twenty-seven months later, CAPTEM was restarted for disease recurrence with ongoing tumor response. The second patient had a rapid tumor regrowth 2 years after his third surgical resection. He was treated with 12 cycles of CAPTEM, which led to tumor shrinkage with no tumor regrowth 22 months after cessation of therapy. Experiments using mouse ACTH-producing pituitary tumor AtT20 cells demonstrated that treatment with 5-fluorouracil in combination with temozolomide had an additive effect in reducing cell viability and ACTH production in the culture medium. Our patients and experimental data in AtT20 cells support CAPTEM as a potential treatment option for aggressive corticotroph tumors and carcinomas. However, a prospective clinical trial is required to determine whether CAPTEM is superior to temozolomide in the treatment of these tumors.
References30
Newest
#1Motoyasu Satou (U of A: University of Alberta)H-Index: 2
#2Jason Wang (U of A: University of Alberta)H-Index: 1
Last. Toru Tateno (U of A: University of Alberta)H-Index: 14
view all 12 authors...
Abstract Pituitary tumors (PTs) can cause significant mortality and morbidity due to limited therapeutic options. L-type amino acid transporters (LATs), in particular, the LAT1 isoform, is expressed in a variety of tumor cells. Pharmacological inhibition or genetic ablation of LAT1 can suppress leucine transport into cancer cells, resulting in suppression of cancer cell growth. However, roles of LAT1 in PTs have not been elucidated. Therefore, we assessed LAT1 expression in PTs and evaluated a L...
4 CitationsSource
#1George PapaxoinisH-Index: 19
#2Zoe KordatouH-Index: 5
Last. Wasat Mansoor (University of Manchester)H-Index: 22
view all 8 authors...
: Background Temozolomide and capecitabine (CAPTEM) chemotherapy is known to be active in patients with pancreatic neuroendocrine tumours (NET). Objective This retrospective analysis set out to describe the efficacy and toxicity of CAPTEM in patients with advanced pulmonary carcinoids (PC). Methods Patients were included with advanced PC who had been treated with a maximum of 6 cycles of oral temozolomide 200 mg/m2 day 10-14 and capecitabine 750 mg/m2 BID day 1-14, repeated every 28 days, follow...
10 CitationsSource
#1Taymeyah Al-ToubahH-Index: 8
#2Brian MorseH-Index: 8
Last. Jonathan R. StrosbergH-Index: 45
view all 3 authors...
BACKGROUND: Patients with advanced lung neuroendocrine neoplasms (NENs) have few treatment options. Capecitabine and temozolomide have recently showed significant activity in patients with pancreatic neuroendocrine tumors (NETs), but data in lung NETs are limited. METHODS: We retrospectively reviewed the records of patients treated at a large referral center to identify patients seen between January 2008 and September 2018 with metastatic lung NENs who received treatment with capecitabine and te...
14 CitationsSource
#1Omalkhaire M. Alshaikh (Islamic University)H-Index: 3
#2Sylvia L. Asa (U of T: University of Toronto)H-Index: 114
Last. Shereen Ezzat (Princess Margaret Cancer Centre)H-Index: 40
view all 4 authors...
Pituitary carcinoma is a rare disease, defined by the presence of cerebrospinal or distant metastasis of a pituitary neuroendocrine tumor (PitNET). To review our institutional experience of pituitary carcinoma, we searched the database of the UHN Endocrine Oncology Site group and the University Health Network pathology laboratory information system from 2001 to 2016. Among 1055 PitNETs from 1169 transsphenoidal resections, we identified 4 cases of pituitary carcinoma, indicating that pituitary c...
21 CitationsSource
#1Yaoheng Lu (Tianjin Medical University General Hospital)H-Index: 2
#2Zhicheng ZhaoH-Index: 5
Last. Weidong LiH-Index: 4
view all 7 authors...
AbstractRetrospective studies have suggested that capecitabine combined with temozolomide (CAPTEM) is effective for treating patients with advanced neuroendocrine neoplasms (NENs); however, the efficacy and safety of this regimen needs to be verified by high-quality evidence or results of randomized
18 CitationsSource
#1Andrew L. Lin (Cornell University)H-Index: 7
#2Philip Jonsson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 30
Last. Eliza B. Geer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 14 authors...
Context: Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and few effective treatment options. Case: A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasizing to the liver. Following treatment with ipilimumab and nivolumab, the tumor volume of the dominant liver metastasis reduced by 92%, and the recurrent intracranial disease regressed by 59%. Simultan...
60 CitationsSource
28 CitationsSource
#1Ann McCormack (St. Vincent's Health System)H-Index: 13
#2Olaf M. Dekkers (LEI: Leiden University)H-Index: 78
Last. Pia BurmanH-Index: 25
view all 7 authors...
OBJECTIVE: To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment.DESIGN: Electronic survey to ESE members Dec 2015-Nov 2016.RESULTS: Reports on 166 patients (40 PC, 125 APT, 1 unclassified) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% of the tumours were clinically functioning, and the most frequent immunohistochemical subtype were corticotroph tumours ...
96 CitationsSource
#1Joseph Wheat (AmeriCorps VISTA)H-Index: 2
#2Thein Myint (UK: University of Kentucky)H-Index: 9
Last. Albert M. Anderson (Emory University)H-Index: 14
view all 35 authors...
AbstractCentral nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has been derived from small single center case series, or case report literature reviews. Therefore, a larger study of central nervous system (CNS) histoplasmosis is n
71 CitationsSource
#1Gérald Raverot (French Institute of Health and Medical Research)H-Index: 42
#2Pia Burman (Lund University)H-Index: 25
Last. Olaf M. DekkersH-Index: 78
view all 8 authors...
BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours...
200 CitationsSource
Cited By2
Newest
#1Tae Nakano-Tateno (U of A: University of Alberta)H-Index: 3
Last. Takako ArakiH-Index: 10
view all 7 authors...
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide r...
Source
#1Mei Luo (SYSU: Sun Yat-sen University)H-Index: 1
#2Yiheng Tan (SYSU: Sun Yat-sen University)H-Index: 1
Last. Haijun Wang (SYSU: Sun Yat-sen University)H-Index: 13
view all 10 authors...
Background: A growing number of evidences suggest that TMZ applications can generate impressive benefits for APT and PC patients. However, the definite role of TMZ for individuals remains unclarified due to the variation between studies. And the predictive factors to alter its efficacy remain debatable. Objective: To evaluate the long-term effectiveness and safety profile of TMZ in the treatment of pituitary malignancies, and delineate the predictors during its clinical employment. Results: A li...
1 CitationsSource